Literature DB >> 327947

Polymyalgia rheumatica. Abrupt and gradual withdrawal of prednisolone treatment, clinical and laboratory observations.

W Esselinckx, S M Doherty, A S Dixon.   

Abstract

Eighteen patients with polymyalgia rheumatica had corticosteroid treatment withdrawn abruptly under close observation. In each case polymyalgic symptoms reappeared but were controlled rapidly when prednisolone was reintroduced. Prednisolone withdrawal was then started by slow decrements of dose. In no patient was it possible to withdraw prednisolone treatment, after using either method, during the period of observation.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 327947      PMCID： PMC1006669          DOI： 10.1136/ard.36.3.219

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  26 in total

1.  Recovery of hypothalamo-pituitary-adrenal function after corticosteroid therapy.

Authors:  T Livanou; D Ferriman; V H James
Journal:  Lancet       Date:  1967-10-21       Impact factor: 79.321

2.  GIANT-CELL MYOCARDITIS WITH MULTIPLE ORGAN INVOLVEMENT.

Authors:  H P PALMER; I E MICHAEL
Journal:  Arch Intern Med       Date:  1965-09

3.  Prognosis in the anarthritic rheumatoid syndrome.

Authors:  L BAGRATUNI
Journal:  Br Med J       Date:  1963-02-23

4.  Polymyalgia rheumatica. A clinical study of 21 cases.

Authors:  I GORDON
Journal:  Q J Med       Date:  1960-10

5.  Giant-cell arteritis, or arteritis of the aged.

Authors:  J W PAULLEY; J P HUGHES
Journal:  Br Med J       Date:  1960-11-26

6.  Blood levels of 17-hydroxycorticosteroids following the administration of adrenal steroids and their relation to levels of circulating leukocytes.

Authors:  D H NELSON; A A SANDBERG; J G PALMER; F H TYLER
Journal:  J Clin Invest       Date:  1952-05       Impact factor: 14.808

7.  Adrenal function after prolonged corticosteroid therapy.

Authors:  B H ROBINSON; D MATTINGLY; C L COPE
Journal:  Br Med J       Date:  1962-06-09

8.  Giant-cell (temporal) arteritis.

Authors:  R H HEPTINSTALL; K A PORTER; H BARKLEY
Journal:  J Pathol Bacteriol       Date:  1954-04

9.  Polymyalgia rheumatica -- a clinical study with particular reference to arterial disease.

Authors:  A G Mowat; B L Hazleman
Journal:  J Rheumatol       Date:  1974-06       Impact factor: 4.666

10.  Polymyalgia rheumatica and temporal arteritis.

Authors:  A S Dixon; C Beardwell; A Kay; J Wanka; Y T Wong
Journal:  Ann Rheum Dis       Date:  1966-05       Impact factor: 19.103
View more
  6 in total

1.  Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

2.  Giant cell arteritis precipitated by a diagnostic trial of prednisolone in suspected polymyalgia rheumatica.

Authors:  P A Reilly; P J Maddison
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

Review 3.  Giant cell arteritis. Epidemiology and treatment.

Authors:  E Nordborg; R Andersson; B A Bengtsson
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

4.  Polymyalgia rheumatica. Assessment of disease activity using erythrocyte sedimentation rate and plasma viscosity.

Authors:  W Esselinckx; R C Bucknall; A S Dixon
Journal:  Ann Rheum Dis       Date:  1977-12       Impact factor: 19.103

5.  Plasma viscosity in giant cell arteritis as a predictor of disease activity.

Authors:  M Gudmundsson; E Nordborg; B A Bengtsson; A Bjelle
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

Review 6.  The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.

Authors:  Amy T Page; Rhonda M Clifford; Kathleen Potter; Darren Schwartz; Christopher D Etherton-Beer
Journal:  Br J Clin Pharmacol       Date:  2016-06-13       Impact factor: 4.335
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.